Treatment duration of trastuzumab in early HER2-positive breast cancer
Record ID 32018005508
English
Details
Project Status:
Ongoing
URL for project:
https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/trastazumab.html
URL for protocol:
https://www.bag.admin.ch/dam/bag/en/dokumente/kuv-leistungen/leistungen-und-tarife/hta/berichte/h0062thtr-hta-protocol.pdf.download.pdf/HTA%20protocol.pdf
Anticipated Publish Date:
2024
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Switzerland
MeSH Terms
- Breast Neoplasms
- Trastuzumab
- Duration of Therapy
- Chemotherapy, Adjuvant
- Receptor, ErbB-2
Keywords
- PROMs
- efficacy
- effectiveness
- safety
- costs
- economics
- cost-effectiveness
- budget impact
- legal
- social
- ethical
- organisational
- trastuzumab
- pertuzumab
- HER2-positive
- breast cancer
- duration of treatment
- reduced treatment duration
- HER2-positive early breast cancer
Contact
Organisation Name:
Swiss Federal Office of Public Health (FOPH)
Contact Address:
Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name:
Stephanie Vollenweider
Contact Email:
hta@bag.admin.ch
Copyright:
Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.